Oncology Institute, Inc. — Form 8-K
Filed July 7, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 48/100
What the filing says
The Oncology Institute, Inc. entered into a credit agreement dated July 1, 2026, with ORBIMED OPPORTUNITIES (CA) V LLC as lender and administrative agent. The agreement provides a $75,000,000 senior term loan facility with a 5-year maturity (due July 1, 2031). Interest accrues at SOFR + 5.75% (minimum 3.00%), with quarterly amortization beginning in Q3 2029 at 7.5% per quarter. Proceeds are used to repay existing indebtedness and general corporate purposes.
Why this rating
Large financing ($75M ≈ 55% of company market cap) materially impacts balance sheet and liquidity but typical terms for healthcare company. Moderate relative significance given company's $137M market value—substantial but not transformational.
See more from July 7, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.